Related Experiment Video
Updated: Dec 29, 2025
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
Jennifer Sun1,2, Barbara Muz1, Kinan Alhallak1,2
1Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
Abstract:
Multiple myeloma (MM) remains to be incurable despite recent therapeutic advances. CD47, an immune checkpoint known as the "don't eat me" signal, is highly expressed on the surface of various cancers, allowing cancer cells to send inhibitory signals to macrophages and impede phagocytosis and immune response. In this study, we hypothesized that blocking the "don't eat me" signaling using an anti-CD47 monoclonal antibody will induce killing of MM cells. We report that CD47 expression was directly correlated with stage of the disease, from normal to MGUS to MM. Moreover, MM cells had remarkably higher CD47 expression than other cell populations in the bone marrow. These findings indicate that CD47 is specifically expressed on MM and can be used as a potential therapeutic target. Further, blocking of CD47 using an anti-CD47 antibody induced immediate activation of macrophages, which resulted in induction of phagocytosis and killing of MM cells in the 3D-tissue engineered bone marrow model, as early as 4 hours. These results suggest that macrophage checkpoint immunotherapy by blocking the CD47 "don't eat me" signal is a novel and promising strategy for the treatment of MM, providing a basis for additional studies to validate these effects in vivo and in patients.
Insights
Blocking the CD47 "don't eat me" signal with an antibody prompts immune cells to eliminate multiple myeloma cells. This macrophage checkpoint immunotherapy shows promise for treating this incurable blood cancer.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Multiple myeloma (MM) is an incurable blood cancer.
- CD47 acts as a "don't eat me" signal, protecting cancer cells from immune attack.
- Targeting CD47 may restore immune recognition and destruction of cancer cells.
Purpose of the Study:
- To investigate the potential of blocking CD47 signaling to induce the killing of multiple myeloma cells.
- To evaluate CD47 expression levels in different stages of myeloma and in bone marrow populations.
Main Methods:
- Quantification of CD47 expression in normal, MGUS, and MM cells.
- Assessment of anti-CD47 antibody effects on macrophage activation and phagocytosis.
- Utilizing a 3D-tissue engineered bone marrow model to simulate the tumor microenvironment.
Main Results:
- CD47 expression positively correlates with disease stage in multiple myeloma.
- Multiple myeloma cells exhibit significantly higher CD47 expression compared to other bone marrow cells.
- Anti-CD47 antibody treatment rapidly activated macrophages, leading to phagocytosis and killing of MM cells within 4 hours.
Conclusions:
- CD47 is a specific and promising therapeutic target for multiple myeloma.
- Macrophage checkpoint immunotherapy via CD47 blockade is a novel and effective strategy against MM.
- Further in vivo and clinical studies are warranted to validate these findings.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy